Identification of the time-point which gives a plasma rabeprazole concentration that adequately reflects the area under the concentration-time curve

Takenori Niioka, Tsukasa Uno, Norio Yasui-Furukori, Mikiko Shimizu, Kazunobu Sugawara, Tomonori Tateishi

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objective: The purpose of this study is to evaluate whether a simple formula using limited blood samples can predict the area under the plasma rabeprazole concentration-time curve (AUC) in co-administration with CYP inhibitors. Methods: A randomized double-blind placebo-controlled crossover study design in three phases was conducted at intervals of 2 weeks. Twenty-one healthy Japanese volunteers, including three CYP2C19 genotype groups, took a single oral 20-mg dose of rabeprazole after three 6-day pretreatments, i.e., clarithromycin 800 mg/day, fluvoxamine 50 mg/day, and placebo. Prediction formulas of the AUC were derived from pharmacokinetics data of 21 subjects in three phases using multiple linear regression analysis. Ten blood samples were collected over 24 h to calculate AUC. Plasma concentrations of rabeprazole was measured by an HPLC-assay (l.l.q.=1 ng/ml). Results: The AUC was based on all the data sets (n=63). The linear regression using two points (C3 and C6) could predict AUC0-∞ precisely, irrespective of CYP2C19 genotypes and CYP inhibitors (AUC0-∞=1.39×C3+7.17×C6+344.14, r 2=0.825, p<0.001). Conclusion: The present study demonstrated that the AUC of rabeprazole can be estimated by the simple formula using two-point concentrations. This formula can be more accurate for the prediction of AUC estimation than that reflected by CYP2C19 genotypes without any determination, even if there are significant differences for the CYP2C19 genotypes. Therefore, this prediction formula might be useful to evaluate whether CYP2C19 genotypes really reflects the curative effect of rabeprazole.

Original languageEnglish
Pages (from-to)855-861
Number of pages7
JournalEuropean Journal of Clinical Pharmacology
Volume62
Issue number10
DOIs
Publication statusPublished - 2006 Oct
Externally publishedYes

Fingerprint

Rabeprazole
Area Under Curve
Genotype
Cross-Over Studies
Linear Models
Placebos
Fluvoxamine
Clarithromycin
Healthy Volunteers
Pharmacokinetics
High Pressure Liquid Chromatography
Regression Analysis
Cytochrome P-450 CYP2C19

Keywords

  • AUC
  • CYP2C19 genotype
  • Limit sampling
  • Phenotype
  • Rabeprazole

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Identification of the time-point which gives a plasma rabeprazole concentration that adequately reflects the area under the concentration-time curve. / Niioka, Takenori; Uno, Tsukasa; Yasui-Furukori, Norio; Shimizu, Mikiko; Sugawara, Kazunobu; Tateishi, Tomonori.

In: European Journal of Clinical Pharmacology, Vol. 62, No. 10, 10.2006, p. 855-861.

Research output: Contribution to journalArticle

Niioka, Takenori ; Uno, Tsukasa ; Yasui-Furukori, Norio ; Shimizu, Mikiko ; Sugawara, Kazunobu ; Tateishi, Tomonori. / Identification of the time-point which gives a plasma rabeprazole concentration that adequately reflects the area under the concentration-time curve. In: European Journal of Clinical Pharmacology. 2006 ; Vol. 62, No. 10. pp. 855-861.
@article{24391a15ee624824a5d5c310cdb4c345,
title = "Identification of the time-point which gives a plasma rabeprazole concentration that adequately reflects the area under the concentration-time curve",
abstract = "Objective: The purpose of this study is to evaluate whether a simple formula using limited blood samples can predict the area under the plasma rabeprazole concentration-time curve (AUC) in co-administration with CYP inhibitors. Methods: A randomized double-blind placebo-controlled crossover study design in three phases was conducted at intervals of 2 weeks. Twenty-one healthy Japanese volunteers, including three CYP2C19 genotype groups, took a single oral 20-mg dose of rabeprazole after three 6-day pretreatments, i.e., clarithromycin 800 mg/day, fluvoxamine 50 mg/day, and placebo. Prediction formulas of the AUC were derived from pharmacokinetics data of 21 subjects in three phases using multiple linear regression analysis. Ten blood samples were collected over 24 h to calculate AUC. Plasma concentrations of rabeprazole was measured by an HPLC-assay (l.l.q.=1 ng/ml). Results: The AUC was based on all the data sets (n=63). The linear regression using two points (C3 and C6) could predict AUC0-∞ precisely, irrespective of CYP2C19 genotypes and CYP inhibitors (AUC0-∞=1.39×C3+7.17×C6+344.14, r 2=0.825, p<0.001). Conclusion: The present study demonstrated that the AUC of rabeprazole can be estimated by the simple formula using two-point concentrations. This formula can be more accurate for the prediction of AUC estimation than that reflected by CYP2C19 genotypes without any determination, even if there are significant differences for the CYP2C19 genotypes. Therefore, this prediction formula might be useful to evaluate whether CYP2C19 genotypes really reflects the curative effect of rabeprazole.",
keywords = "AUC, CYP2C19 genotype, Limit sampling, Phenotype, Rabeprazole",
author = "Takenori Niioka and Tsukasa Uno and Norio Yasui-Furukori and Mikiko Shimizu and Kazunobu Sugawara and Tomonori Tateishi",
year = "2006",
month = "10",
doi = "10.1007/s00228-006-0184-1",
language = "English",
volume = "62",
pages = "855--861",
journal = "European Journal of Clinical Pharmacology",
issn = "0031-6970",
publisher = "Springer Verlag",
number = "10",

}

TY - JOUR

T1 - Identification of the time-point which gives a plasma rabeprazole concentration that adequately reflects the area under the concentration-time curve

AU - Niioka, Takenori

AU - Uno, Tsukasa

AU - Yasui-Furukori, Norio

AU - Shimizu, Mikiko

AU - Sugawara, Kazunobu

AU - Tateishi, Tomonori

PY - 2006/10

Y1 - 2006/10

N2 - Objective: The purpose of this study is to evaluate whether a simple formula using limited blood samples can predict the area under the plasma rabeprazole concentration-time curve (AUC) in co-administration with CYP inhibitors. Methods: A randomized double-blind placebo-controlled crossover study design in three phases was conducted at intervals of 2 weeks. Twenty-one healthy Japanese volunteers, including three CYP2C19 genotype groups, took a single oral 20-mg dose of rabeprazole after three 6-day pretreatments, i.e., clarithromycin 800 mg/day, fluvoxamine 50 mg/day, and placebo. Prediction formulas of the AUC were derived from pharmacokinetics data of 21 subjects in three phases using multiple linear regression analysis. Ten blood samples were collected over 24 h to calculate AUC. Plasma concentrations of rabeprazole was measured by an HPLC-assay (l.l.q.=1 ng/ml). Results: The AUC was based on all the data sets (n=63). The linear regression using two points (C3 and C6) could predict AUC0-∞ precisely, irrespective of CYP2C19 genotypes and CYP inhibitors (AUC0-∞=1.39×C3+7.17×C6+344.14, r 2=0.825, p<0.001). Conclusion: The present study demonstrated that the AUC of rabeprazole can be estimated by the simple formula using two-point concentrations. This formula can be more accurate for the prediction of AUC estimation than that reflected by CYP2C19 genotypes without any determination, even if there are significant differences for the CYP2C19 genotypes. Therefore, this prediction formula might be useful to evaluate whether CYP2C19 genotypes really reflects the curative effect of rabeprazole.

AB - Objective: The purpose of this study is to evaluate whether a simple formula using limited blood samples can predict the area under the plasma rabeprazole concentration-time curve (AUC) in co-administration with CYP inhibitors. Methods: A randomized double-blind placebo-controlled crossover study design in three phases was conducted at intervals of 2 weeks. Twenty-one healthy Japanese volunteers, including three CYP2C19 genotype groups, took a single oral 20-mg dose of rabeprazole after three 6-day pretreatments, i.e., clarithromycin 800 mg/day, fluvoxamine 50 mg/day, and placebo. Prediction formulas of the AUC were derived from pharmacokinetics data of 21 subjects in three phases using multiple linear regression analysis. Ten blood samples were collected over 24 h to calculate AUC. Plasma concentrations of rabeprazole was measured by an HPLC-assay (l.l.q.=1 ng/ml). Results: The AUC was based on all the data sets (n=63). The linear regression using two points (C3 and C6) could predict AUC0-∞ precisely, irrespective of CYP2C19 genotypes and CYP inhibitors (AUC0-∞=1.39×C3+7.17×C6+344.14, r 2=0.825, p<0.001). Conclusion: The present study demonstrated that the AUC of rabeprazole can be estimated by the simple formula using two-point concentrations. This formula can be more accurate for the prediction of AUC estimation than that reflected by CYP2C19 genotypes without any determination, even if there are significant differences for the CYP2C19 genotypes. Therefore, this prediction formula might be useful to evaluate whether CYP2C19 genotypes really reflects the curative effect of rabeprazole.

KW - AUC

KW - CYP2C19 genotype

KW - Limit sampling

KW - Phenotype

KW - Rabeprazole

UR - http://www.scopus.com/inward/record.url?scp=33749457934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749457934&partnerID=8YFLogxK

U2 - 10.1007/s00228-006-0184-1

DO - 10.1007/s00228-006-0184-1

M3 - Article

C2 - 16915367

AN - SCOPUS:33749457934

VL - 62

SP - 855

EP - 861

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

SN - 0031-6970

IS - 10

ER -